Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Stopped early · Phase 2
Conditions studied: Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
In brief
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate works in treating patients with recurrent transitional cell bladder cancer.
Key facts
- Study ID
- NCT01118351
- Run by
- Case Comprehensive Cancer Center
- People needed
- 19
- Starts
- 2008-10-01
- Expected to finish
- 2015-09-01
- Last updated by the study team
- 2019-05-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CCF-Fairview Hospital — Cleveland, Ohio, United States
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.